BioDelivery Sciences International, Inc. (BDSI) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01, Briefing.com reports. The business had revenue of $11.25 million during the quarter, compared to analysts’ expectations of $9.40 million. BioDelivery Sciences International had a return on equity of 35.59% and a net margin of 10.40%. BioDelivery Sciences International’s revenue was up 215.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.30) earnings per share.
Shares of BioDelivery Sciences International (NASDAQ:BDSI) opened at $2.65 on Friday. BioDelivery Sciences International has a 12-month low of $1.50 and a 12-month high of $3.60. The company has a quick ratio of 1.24, a current ratio of 1.45 and a debt-to-equity ratio of 1.34.
In related news, insider Mark A. Sirgo sold 201,373 shares of BioDelivery Sciences International stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $2.84, for a total transaction of $571,899.32. Following the completion of the sale, the insider now owns 1,509,262 shares of the company’s stock, valued at $4,286,304.08. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Mark A. Sirgo sold 65,405 shares of BioDelivery Sciences International stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $2.75, for a total value of $179,863.75. Following the sale, the chief executive officer now directly owns 1,509,262 shares of the company’s stock, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 402,127 shares of company stock valued at $1,142,798. Insiders own 9.00% of the company’s stock.
A hedge fund recently raised its stake in BioDelivery Sciences International stock. Northern Trust Corp grew its stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 0.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 140,450 shares of the specialty pharmaceutical company’s stock after buying an additional 1,203 shares during the period. Northern Trust Corp owned approximately 0.25% of BioDelivery Sciences International worth $394,000 as of its most recent SEC filing. 41.80% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently commented on BDSI shares. HC Wainwright started coverage on BioDelivery Sciences International in a research report on Sunday, September 10th. They issued a “buy” rating and a $5.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of BioDelivery Sciences International in a research report on Sunday, August 20th. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Janney Montgomery Scott raised their target price on BioDelivery Sciences International from $3.00 to $4.00 and gave the stock a “fair value” rating in a research report on Monday, July 24th. Finally, Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Sunday, October 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. BioDelivery Sciences International has a consensus rating of “Buy” and a consensus target price of $4.29.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.